Phase 3 N=29 D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia
Phobic Disorders
Primary: Acrophobia Questionnaire With Avoidance (AAVQ) — 9.00; 12.38 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=97 Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women
Postmenopausal Osteoporosis
Primary: % Change From Baseline BMD in L1-L4 Axial Lumbar Spine at Week 24 — 5.07; 2.21; -0.17 percentage of change
Phase 2 N=159 Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.
Cachexia
Primary: The Efficacy of GTx-024 on Total Body Lean Mass. — 1.55; 0.98; 0.02 kg
N/A N=103 Safety and Efficacy of Juvederm® VOLUMA™ for Correction of Mid-face Volume Deficiency
Mid-face Volume Deficiency
Primary: Percentage of Participants With a ≥ 1 Point Improvement From Baseline in the Subject's Global Aesthetic Improvement Scale (GAIS) at Week 4 — 97.06 percentage of…
Phase 4 N=73 Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects
Pulmonary Arterial Hypertension
Primary: Number of Adverse Events — 440; 266; 41; 15 number of events
Phase 2 N=16 Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease
Cystic Fibrosis
Primary: Change in Mucociliary Clearance — 7.4; 9.5 percent clearance
N/A N=572 Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Proportion of Subjects in Each Treatment Group With Therapeutic Cure — 105; 93 participants
N/A N=70 Trial Comparing Dual Probe Ultrasonic Lithotripsy to a Single Probe Ultrasonic Lithotripsy
Kidney Stones
Primary: Kidney Stone Clearance Rate — 61.9; 75.8 mm^2/min
Phase 1 N=59 Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis
Psoriasis · Immunomodulation
Primary: Change From Baseline in QT Interval at 1 Hour Post Morning Dose (HPD 1) on Day 1 — 372.20; 348.47; 369.40; 375.74 millisecond (msec)
N/A N=16 Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection
HIV Infections
Primary: Plasma HIV-1 Viral Load (Copies/ml) at Week 24 as Compared Between the Two Arms — 4.8627; 4.2620 Log 10 copies of virus/ml
N/A N=100 Intubation of Morbidly Obese Patients. A Clinical Trial, Comparing Glide Scope ® With Fastrach TM
Morbidly Obese · Intubationtime · Intubationattempts
Primary: Number of Patients Intubated in the First Attempt — 42; 46 participants
N/A N=144 The Use of Progesterone to Reduce Preterm Birth
Preterm Birth
Primary: Weeks Gestation at Birth Among Patients Receiving the Active Drug. — 31.9; 30.2 weeks
Phase 2 N=29 Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery
Esophageal Cancer
Primary: Pathologic Complete Response — 16.7 percentage of participants
N/A N=52 Ghrelin Levels in Children With Poor Growth
Idiopathic Short Stature · Failure to Thrive
Primary: Total Ghrelin Level — 1063; 1264; 1157 pg/mL
N/A N=37 Safety for Frequent Use Conditions of Hair Removal Device
Hair Removal
Primary: Percentage of Participants With Device Related Anticipated Skin Effects, Serious Adverse Events, or Adverse Events. — 0; 0; 0 percentage of particpants